Publicaciones en colaboración con investigadores/as de Aalborg University (16)

2024

  1. Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry

    European Journal of Pediatrics, Vol. 183, Núm. 8, pp. 3567-3578

  2. Global trends in opioid use for pain management in acute pancreatitis: A multicentre prospective observational study

    United European Gastroenterology Journal, Vol. 12, Núm. 8, pp. 1114-1127

2023

  1. Corrigendum to “Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry” [Digestive and Liver Disease Volume 55, Issue 3, March 2023, Pages 350–359] (Digestive and Liver Disease (2023) 55(3) (350–359), (S1590865822007289), (10.1016/j.dld.2022.09.020))

    Digestive and Liver Disease

  2. Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry

    Digestive and Liver Disease, Vol. 55, Núm. 3, pp. 350-359

  3. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

    eClinicalMedicine, Vol. 63

  4. Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry

    Journal of Thrombosis and Thrombolysis

2022

  1. Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry

    United European Gastroenterology Journal, Vol. 10, Núm. 5, pp. 507-517

  2. Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry

    International Journal of Clinical Practice, Vol. 2022

  3. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

    Clinical Research in Cardiology, Vol. 111, Núm. 5, pp. 560-573

  4. Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (Clinical Research in Cardiology, (2022), 111, 5, (560-573), 10.1007/s00392-022-01996-2)

    Clinical Research in Cardiology

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

  2. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078))

    Nature communications

2020

  1. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

2019

  1. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

    Nature Communications, Vol. 10, Núm. 1

2017

  1. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

    Nature Genetics, Vol. 49, Núm. 12, pp. 1767-1778

2015

  1. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?: The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation

    Circulation: Cardiovascular Quality and Outcomes, Vol. 8, pp. S12-S20